Kissei Pharmaceutical revised the package insert regarding liver function disorder for the therapeutic drug Tabneuvos and issued a safety information flash to alert healthcare professionals. The company requests caution in using the drug for new patients and thorough liver function testing for ongoing patients. The impact on financial performance is currently uncertain.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4547-20260521-01.pdf","jir_short_summary":"Kissei Pharmaceutical revised the package insert regarding liver function disorder for the therapeutic drug Tabneuvos and issued a safety information flash to alert healthcare professionals. The company requests caution in using the drug for new patients and thorough liver function testing for ongoing patients. The impact on financial performance is currently uncertain.","jir_summary":"### Safety Information and Package Insert Revision\nKissei Pharmaceutical has revised the package insert concerning liver function disorder to enhance the safety of the designated intractable disease treatment drug Tabneuvos, and has called on healthcare professionals to avoid using the drug for new patients and to conduct thorough liver function tests. This revision aims to address the risk of severe liver function disorder and ensure patient safety. The revision was implemented on May 15, 2026, and a safety information flash was also issued to raise awareness.\n\n### Future Actions and Impact on Performance\nThe company is currently reviewing the potential impact of this matter on its financial performance and will disclose findings promptly once determined. It is focusing on providing proper information and guidance to healthcare professionals and patients to promote safe drug use. The company continues to strive for safety in medical practice and the health of patients and is monitoring the potential impact on earnings.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #IRRelated, #JapaneseStocks","jir_key_figures":"Unknown\nUnknown\nUnknown","jir_meta_title":"\u3010Kissei Pharmaceutical\u3011Safety Information Flash and Reminder for Medicinal Products\uff5cMay 2026","jir_meta_description":"Kissei Pharmaceutical revised the package insert regarding liver function disorder for the therapeutic drug Tabneuvos and issued a safety information flash. The impact on financial performance is currently uncertain. Promoting safe drug use.","jir_og_title":"\u3010Kissei Pharmaceutical\u3011Safety Information Flash and Reminder for Medicinal Products\uff5cMay 2026","jir_og_description":"Kissei Pharmaceutical revised the package insert for drug safety enhancement and issued a reminder. The impact on financial performance is currently uncertain.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"disclosure_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-53488","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n